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Abstract
Neisseria meningitidis is a leading cause of sepsis and meningitis. The bacterium recruits factor H (fH), a negative regulator of
the complement system, to its surface via fH binding protein (fHbp), providing a mechanism to avoid complement-
mediated killing. fHbp is an important antigen that elicits protective immunity against the meningococcus and has been
divided into three different variant groups, V1, V2 and V3, or families A and B. However, immunisation with fHbp V1 does
not result in cross-protection against V2 and V3 and vice versa. Furthermore, high affinity binding of fH could impair
immune responses against fHbp. Here, we investigate a homologue of fHbp in Neisseria gonorrhoeae, designated as
Gonococcal homologue of fHbp (Ghfp) which we show is a promising vaccine candidate for N. meningitidis. We
demonstrate that Gfhp is not expressed on the surface of the gonococcus and, despite its high level of identity with fHbp,
does not bind fH. Substitution of only two amino acids in Ghfp is sufficient to confer fH binding, while the corresponding
residues in V3 fHbp are essential for high affinity fH binding. Furthermore, immune responses against Ghfp recognise V1, V2
and V3 fHbps expressed by a range of clinical isolates, and have serum bactericidal activity against N. meningitidis
expressing fHbps from all variant groups.
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Introduction
The Gram negative bacterium Neisseria meningitidis is part of the
normal human nasopharyngeal flora in up to 40% of healthy
individuals [1,2] and a leading cause of sepsis and meningitis
worldwide, with a case fatality rate from septicaemia of
approximately 10% [3,4]. Because of the non-specific early
symptoms and rapid progression of meningococcal disease, there
is an urgent need to develop vaccines to protect individuals from
this important infection [4,5]. N. meningitidis is classified into 12
different serogroups based on its polysaccharide capsule, although
only six serogroups are responsible for the majority of disease.
Currently there are vaccines based on the polysaccharide capsule
of four of these serogroups (i.e. A, C, W, and Y) [5]. However, the
capsule of serogroup B N. meningitidis (MenB) is structurally
identical to a modification of a cell adhesion molecule present in
the foetal brain, and is thus weakly immunogenic and could induce
autoimmunity if used as a vaccine [6]. Vaccines based on outer
membrane vesicles have proven to be effective against MenB but
only in combating epidemic disease caused by a single clone [7];
the most effective approach to produce a broadly protective
vaccine against all N. meningitidis serogroups (including MenB) will
be the use of protein based vaccines [8].
Factor H binding protein (fHbp) of N. meningitidis is an important
component of MenB vaccines currently under advanced clinical
development [8,9]. Immunisation with fHbp elicits serum
bactericidal antibodies [8,9], a marker of protection, and the
protein provides an important mechanism for immune evasion for
the meningococcus by recruiting the negative complement
regulator, factor H (fH), thereby protecting N. meningitidis against
complement-mediated lysis [10,11]. fHbp is a surface expressed
lipoprotein consisting of two b barrels [12,13]. Based on sequence
alignments, fHbp has been categorised into three different variant
groups, V1, V2 and V3, or two families, A and B [8,9]. However,
immunisation with V1 fHbp (family B) does not elicit bactericidal
responses against V2 and V3 (family A) fHbp-expressing strains
and vice versa [8,9,14]. In addition, immunisation with one V1
peptide does not provide cross-protection against all strains
expressing V1 fHbps [14]. This suggests that a broadly protective
vaccine should include multiple fHbps, or fHbps which elicit cross-
protection. Current vaccines contain V1.1 fHbp together with
other antigens, or a combination of V1 and V3 fHbps [8,9].
Although Neisseria gonorrhoeae binds fH to its surface, the receptor
on the bacterium is Por1A which is not related to fHbp [15].
However, inspection of gonococcal genome reveals a homologue
of fhbp (annotated as ngo0033 in N. gonorrhoeae strain FA1090); we
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designated the predicted protein Gonococcal homologue of fHbp
(Ghfp), because it is approximately 90% identical to V3 fHbps. In
contrast to meningococcal fHbp, Ghfp is highly conserved with
three alleles described which only differ by one or two amino acids
[16]. Furthermore, Ghfp is not predicted to contain a signal
sequence or a lipid modification motif (LXXC) suggesting it is
unlikely to be expressed on the bacterial surface [16,17]. Here, we
investigate the location, the fH binding capacity and the vaccine
potential of Ghfp.
Results
Ghfp is not surface expressed
Analysis of the genome sequence of N. gonorrhoeae strain FA1090
identified the presence of a fhbp homologue [16,17] which we
designated Gonococcal homologue of fHbp , Ghfp. Sequence
alignment of Ghfp with available fHbp sequences (www.neisseria.
org) reveals that Ghfp has between 60–67%, 81–89% and 86–94%
amino acid identity with V1, V2 and V3 fHbps, respectively
(Supplementary Figure S1). To investigate the cellular location of
Ghfp, sera were raised against recombinant Ghfp from N. gonorrhoeae
strain FA1090. By Western blot analysis, sera recognised a protein
with an estimated molecular weight of 30 kDa (corresponding to
Ghfp) in lysates of N. gonorrhoeae strains FA1090 and F62; no protein
was detected in lysates from F62Dghfp (Figure 1A). Sera raised
against Ghfp also recognise V3.28 fHbp expressed by N. meningitidis
strain M1239 (Figure 1A). Moreover, Ghfp was expressed by 20
clinical N. gonorrhoeae strains isolated in the UK (Figure 1B and not
shown). To determine whether Ghfp is surface located, we
performed flow cytometry analysis with anti-Ghfp serum to detect
Ghfp on the surface of N. gonorrhoeae F62 and F62Dghfp, and fHbp on
N. meningitidis M1239 and M1239Dfhbp (Figure 1C and 1D). Results
demonstrate that anti-Ghfp serum recognises V3.28 fHbp on the
surface of N. meningitidis, but there was no detectable Ghfp on the
gonococcal surface.
To exclude the possibility that the lack of detection of Ghfp by
flow cytometry was due to low expression levels, we also exposed
viable bacteria to proteinase K, and monitored the degradation of
Ghfp, a surface protein i.e. the a-2,3-sialyltransferase, Lst [18], and
the cytoplasmic protein RecA by Western blot analysis. Ghfp and
RecA were unaffected by exposing cells to proteinase K. The
relative amounts of full length protein after incubation with
reducing concentrations of proteinase K (serial three-fold dilutions
from 3 ng/ml, Figure 1E) were: Ghfp, 94-90-89-100; RecA, 101-
98-101-100. In contrast, digestion of Lst was observed : the
amount of Lst peptides with reducing concentrations of proteinase
K were 214-158-128-100 (Figure 1E). Recombinant Ghfp is
cleaved by these concentrations of proteinase K (data not shown)
demonstrating that Ghfp is susceptible to cleavage by this protease.
In conclusion, our results demonstrate that Ghfp is expressed by N.
gonorrhoeae but is not located on the bacterial surface, in keeping
with previous predictions.
Identification of residues responsible for low affinity
binding of Ghfp to fH
Due to its high sequence identity with V3 fHbp, which binds fH
with a KD in the nM range [13,14], fH binding to Ghfp was tested
by far Western analysis. Surprisingly, there was no detectable fH
binding to Ghfp using normal human serum as the source of fH
(Figure 2A). Therefore, we compared the sequence of Ghfp with
V2 and V3 fHbps that bind fH at high affinity, and identified five
amino acids that are consistently different between Ghfp and V2/
V3 fHbps i.e. R176, D199, D212, R288 and D318 of Ghfp (amino
acid numbering according to fHbp V1.1 structure [12], Supple-
mentary data Figure S2). Recent studies have shown that Ghfp is
highly conserved [16] which we confirmed by sequencing Ghfp in
a panel of 20 clinical isolates from the UK (not shown). All three
Ghfp polymorphisms in our isolates had been identified previously
[16] and are also present in V2 and/or V3 fHbp, so do not include
residues (R176, D199, D212, R288 and D318) that are unique to
Ghfp. The amino acids R176 and D199 are located in the
predicted N-terminal barrel of Ghfp and, similar to C-terminal b
barrel residue D212, are not located at the region of Ghfp
corresponding to the interface of fHbp with fH [13]. In contrast,
R288 is located in close proximity to the predicted fH:Ghfp
interface, while D318 could be involved in interactions between
the two predicted b barrels of Ghfp. To determine whether these
five amino acid changes are responsible for the reduced fH
binding to Ghfp, we modified these specific amino acids into the
equivalent residues in the closely related V3.45 fHbp. Modifica-
tion of all five residues in GhfpM1–5 (i.e. R176Q, D199G, D212S,
R288H and D318G) was sufficient to enable Ghfp to bind fH by
far Western analysis (Figure 2B). Analysis of GhfpM1 (R176Q),
GhfpM1–2 (R176Q and D199G), GhfpM1–3 (R176Q, D199G and
D212S) and GhfpM1–4 (R176Q, D199G, D212S and R288H)
demonstrated that these modifications did not restore fH binding.
However the substitutions R288H and D318G in GhfpM4–5 are
sufficient to confer fH binding to Ghfp by far Western analysis
(Figure 2C). To further analyse this interaction in more detail, the
binding of Ghfp and V3.45 fHbp to fH6–7 was also investigated by
Surface Plasmon Resonance (SPR, Figures 2D and 2E). The
dissociation constant of V3.45 fHbp and complement control
protein (CCP) domains 6 and 7 of fH (fH6–7) was 164 nM, similar
to previous results for V3 fHbps [13,14]. Consistent with our far
Western analysis, no fH binding was detected to Ghfp by SPR
under these conditions. Moreover, no fH binding was observed to
GhfpM5 (D318G). There was fH binding detected to GhfpM4
(R288H) (KD of 1660.3 nM) while the double substitution,
GhfpM4–5 (R288H and D318G), resulted in fH binding that was
equivalent to fHbp (KD i.e. of 2 nM).
To exclude the possibility that Ghfp interacts with fH via CCP
domains other than fH6–7, we also examined fH binding by ELISA
in which recombinant proteins were coated on the wells of plates
and binding to purified full length fH was detected. Consistent
with SPR, we observed fH binding to GhfpM4–5, partial fH
Author Summary
Neisseria meningitidis is a major cause of sepsis and
meningitis in young children and adolescents. Although
vaccines are currently available against several serogroups,
a broadly effective vaccine against serogroup B is still
needed. Factor H binding protein (fHbp) can bind the
human complement regulator factor H (fH) and is an
important meningococcal immunogen. fHbp is divided
into three variant groups (V1, V2 and V3) and immunisa-
tion with V1 fHbp does not elicit cross-protection against
meningococcus expressing fHbp V2 or V3, and vice versa.
Here, we investigate a homologue of fHbp in Neisseria
gonorrhoeae which we named Gonococcal homologue of
factor H binding protein (Ghfp). We show that in contrast
to fHbp, Ghfp is not expressed on the bacterial surface and
is unable to bind to factor H. Surprisingly, we found that
antibodies raised against Ghfp have the capacity to
mediate protective immunity against N. meningitidis
expressing any of the three variant groups of fHbp, and
could provide a broadly protective vaccine against N.
meningitidis.
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binding to GhfpM4, and no fH binding to wild-type Ghfp or
GhfpM5 (Figures 2E). In conclusion, despite its high amino acid
identity with V3 fHbp, Ghfp does not bind fH to any significant
degree, and there are only two amino acids responsible for the
striking difference in affinity compared with fHbp. Due to its high
sequence identity with V3 fHbp, we were able to map the Ghfp
sequence on our V3 fHbp structure [13]. Figure 2G shows the
location of these two important amino acids, R288 (altered in M4)
and D318 (M5); while R288 lies on the face of Ghfp which
interacts with fH in fHbps, D318 may influence the interaction
between the two b barrels of the protein.
fH binding to modified V3.45 fHbp
As the modifications R288H and D318G in Ghfp are sufficient
to confer high affinity fH binding, we next investigated whether
the corresponding residues in V3.45 fHbp are necessary for
binding to fH. We generated V3.45 fHbp with H288R and
G318D (fHbpM4–5); these modifications were not included in our
recent analysis of fH:V3 fHbp interactions which involved alanine
substitution of fHbp [13]. Initially binding of fH was examined by
far Western analysis (Figure 3A) and showed loss of detectable fH
binding to fHbpM4 (H288R), fHbpM5 (G318D) or fHbpM4–5
(H288R and G318D). To verify these results, binding of fH6–7 to
fHbp wild type and modified proteins was analysed by SPR
(Figure 3B). No detectable binding of fH was observed to fHbpM4,
fHbpM5 and fHbpM4–5 under these conditions, demonstrating that
both of these residues are necessary for high affinity interactions
with fH. To exclude the possibility that these modified fHbp
molecules interact with fH via CCP domains other than fH6–7, we
examined binding to purified full length fH by ELISA. Consistent
Figure 1. Ghfp is not expressed on the surface of N. gonorrhoeae. (A) Western blot analysis of Ghfp expression by N. gonorrhoeae strains F62,
F62Dghfp and FA1090, and fHbp V3.28 expressed by N. meningitidis strains M1239 and M1239Dfhbp using anti-Ghfp serum. (B) Western blot analysis
of Ghfp expressed by a panel of clinical N. gonorrhoeae isolates (GC1-11, inclusive). Surface expression of Ghfp (C) and fHbp V3.28 (D) was assessed by
flow cytometry analysis using anti-Ghfp serum. Error bars, SEM of three separate experiments; ** p,0.05 and NS (not significant, Student’s t-test).
Representative flow cytometry overlays are shown below the graphs. Bacteria incubated without anti-Ghfp serum are shown as the grey filled areas.
(E) Bacteria were exposed to proteinase K (3 ng/ml and serial three-fold dilutions) and the effect on proteins (shown) determined by Western blot
analysis using anti-Ghfp, anti-RecA and anti- a-Lst serum.
doi:10.1371/journal.ppat.1003528.g001
Gonococcal Homologue of fHbp
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Figure 2. fH binding capacity of Ghfp. (A-C) fH binding to wild type and modified Ghfp and fHbp V3.45 was assessed by far Western analysis
using normal human serum as the source of fH. Western blots are representatives of three separate experiments. Molecular mass is shown in kDa. (D)
Typical equilibrium fit for binding of fH6–7 to Ghfp
M4–5. (E) SPR was performed with Ghfp, GhfpM4 (R288H), GhfpM5 (D318G) and GhfpM4–5 (R288H/
D318G); NBD, no binding detected. (F) Detection of full length fH (5 nM) binding to wild-type and modified Ghfp by ELISA. Error bars, SEM of three
separate experiments; *** p,0.01 and * p,0.1 (Student’s t-test). (G) Cartoon presentation of the predicted structure of Ghfp (Yellow) and fH (Blue).
Residues M1 (R176), M2 (D199) and M3 (D212) are shown in green while those amino acids that are important for fH binding, M4 (R288) and M5
(D318G), are shown in red.
doi:10.1371/journal.ppat.1003528.g002
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with SPR, we observed fH binding to fHbp V3.45 but no binding
to fHbpM4, fHbpM5 and fHbpM4–5 (Figure 3C). Taken together,
we conclude that the amino acids present at positions 288 and 318
are the basis for the profound difference in interactions with fH
observed in the closely related proteins from the gonococcus and
meningococcus.
Immunogenicity of Ghfp
Next we investigated the vaccine potential of Ghfp by
examining the ability of sera raised against this protein to
recognise fHbps expressed by a range of N. meningitidis isolates.
Immune sera not only recognise closely related V3 fHbps
expressed in whole cell extracts of N. meningitidis but also V1 and
V2 proteins (Figure 4A). However, V2.23 fHbp expressed by N.
meningitidis strain 5/99 was not detected by anti-Ghfp serum or by
sera raised against V2 fHbp [19], suggesting that this strain
expresses little or no fHbp. Therefore, we examined whether anti-
Ghfp serum recognises equivalent amounts of different recombi-
nant fHbps by ELISA. Surprisingly, immune sera raised against
Ghfp detected all V1, V2 and V3 fHbps examined (Figure 4B and
C). Serum bactericidal activity (SBA) is an established correlate of
protective immunity against serogroup C meningococcal infection
[8]. To determine whether immunisation with Ghfp elicits
functional immune responses, we evaluated the SBA of anti-Ghfp
serum against several N. meningitidis strains expressing V1, V2 and
V3 fHbp (Figure 4D). We found SBA against strains expressing
V1, V2 and V3 fHbps.
SBA can be influenced by expression levels of fHbp or inherent
serum resistance of the bacteria due to capsule expression [20]. To
study the observed cross-protection of anti-Ghfp serum indepen-
dent of these factors, we constructed isogenic strains of N.
meningitidis MC58 each expressing one of the seven most prevalent
fHbps (i.e. V1.1, V1.4, V1.13, V2.16, V2.19, V3.45 and V3.47)
from disease isolates in England and Wales, accounting for 70% of
cases [19]. To this end, we inactivated the wild-type copy of fHbp
and introduced a single copy of the gene encoding each of the
selected variants at an ectopic site under the control of an IPTG
inducible promoter. Expression of the different fHbps was
confirmed by Western blot analysis of whole cell extracts
(Figure 5A) and surface expression verified by flow cytometry
(Figure 5B and C), showing higher expression levels compared to
wild type fHbp expression. We determined the SBA of anti-Ghfp
serum against the isogenic N. meningitidis strains and compared the
findings with sera raised against V1.1 or V3.45 fHbp (Figure 5D).
We found that anti-Ghfp serum exhibited SBA against N.
meningitidis expressing V1.1, V1.4, V2.16, V2.19, V3.45 and
V3.47. In contrast, anti-fHbp V1.1 serum only elicited SBA
responses against V1.1 and V1.4 expressing strains, while anti-
V3.45 fHbp serum had SBA against all V2 as well as the V3.45
expressing strains (i.e. strains expressing family A proteins). No
detectable SBA was measured with any sera against the isogenic
Figure 3. fH binding to modified fHbp V3.45. (A) Analysis of fH binding to modified V3.45 fHbp by far Western using normal human serum as
the source of fH. Molecular mass is shown in kDa. (B) SPR values of fH6–7 binding to wild type and modified V3.45 fHbp; NBD, no binding detected. (C)
Detection of full length fH (5 nM) binding to wild-type and modified V3.45 fHbp by ELISA. Data represents the mean 6 SEM of three different
experiments.
doi:10.1371/journal.ppat.1003528.g003
Gonococcal Homologue of fHbp
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MC58Dfhbp strain or using sera from mice receiving adjuvant
alone (data not shown). To examine this cross-protection in
another genetic background, we constructed isogenic strains of N.
meningitidis H44/76 in a similar way to express V1.1, V2.16 or
V3.47, and observed similar cross-protective SBA responses
(Figure 5E). In conclusion, Ghfp can elicit SBA against V1, V2
and V3 fHbp expressing N. meningitidis and is therefore a naturally
occurring protein capable of providing cross-protection.
Discussion
N. meningitidis and N. gonorrhoeae are two human specific, closely
related pathogens that inhabit distinct niches in the body. N.
gonorrhoeae causes sexually transmitted infections predominantly
affecting the mucous membranes of the genito-urinary tract, while
N. meningitidis colonises the nasopharynx [21]. Despite sharing
many similarities of the genetic level, these bacteria employ
entirely different mechanisms to evade immune responses, and in
particular, to avoid complement activation on their surface [22].
For example, disease isolates of N. meningitidis express a poly-
saccharide capsule which is essential for high-level serum
resistance [23], while N. gonorrhoeae is not encapsulated. Instead
sialylation of lipopolysaccharide markedly promotes complement
resistance in the gonococcus [24] but this has less impact on N.
meningitidis [25].
Both organisms have evolved to bind fH to their surface to
prevent complement activation (by down-regulating the alternative
pathway) but use different strategies. The gonococcus recruits fH
via an exposed surface loop of Por1A (loop 5), an outer membrane
porin often expressed by isolates recovered from patients [15]. fH
can also bind to gonococci expressing Por1B albeit to a lesser
degree, with this interaction facilitated by lipopolysaccharide
sialylation [26]. Although meningococci express class 3 and class 2
porins (which are related to Por1A and Por1B of N. gonorrhoeae,
respectively), these are not involved in fH binding; loop 5 of the
meningococcal porins lacks a region present in gonococcal Por1A,
which probably accounts for its inability to bind fH [27]. Instead,
the surface expressed lipoprotein fHbp mediates high affinity
binding of fH by the meningococcus irrespective of variant group
[13]. This interaction enhances bacterial survival in whole blood
and prevents serum dependent killing [10,11]. It is not clear why
the organisms have adopted alternative approaches to exploit the
same human molecule, but it is likely to be influenced by the
affinity of the interaction, the local availability of fH and the
density of the bacterial receptor, as well as other factors conferring
complement resistance. Without capsules, gonococci are largely
Figure 4. Immunogenicity of Ghfp. (A) Detection of fHbp variants in whole cell lysates of N. meningitidis by Western blot analysis using anti-Ghfp
serum. Recognition of recombinant V1 (B), and V2and V3 (C) fHbps by anti-Ghfp serum by ELISA. (D) SBA responses for anti-Ghfp serum.
doi:10.1371/journal.ppat.1003528.g004
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reliant on their capacity to recruit fH and C4bp to survive in the
human host [28,29]. Therefore the relatively low levels of fH in the
genito-urinary tract may have favoured its recruitment by a highly
abundant protein on the gonococcal surface, such as porin.
Here, we show that Ghfp, the gonococcal homologue of the
meningococcal fH receptor, does not bind fH to any detectable
extent despite its high sequence identity with fHbp. Remarkably,
only two amino acids in Ghfp (R288 and D318) that differ from
those in fHbp are responsible for this lack of interaction.
Furthermore, the replacement of the equivalent amino acids in
V3.45 fHbp (i.e. H288R and G318D) resulted in loss of fH
binding. The H288R modification is located at the fH:fHbp
interface; the side chain of fHbp H288 sits in a hydrophobic
pocket in fH formed by H337, Y353 and the methylene groups of
the R341. The extended side chain of Ghfp R288 is too long to fit
into this pocket without remodelling the interface, and would also
result in electrostatic repulsion with R341 of fH. The lack of fH
binding to V3.45 fHbpM5 (i.e. G318D) is more difficult to explain
as it is located away from the fH:fHbp interface, and is at the end
of the final strand of the second b barrel. However, the register of
this strand is such that the side chain of residue 318 points into the
hydrophobic core of the barrel. Substitution of Gly with Asp is not
possible without structural rearrangement due to steric clashes in
the hydrophobic core as it is energetically unfavourable to place a
negative charge in the hydrophobic environment. Given this final
strand also makes crucial contacts with the first b barrel, this
substitution could lead to structural rearrangements at interface
between the two barrels and therefore alter the distal fH binding
site (which comprises both barrels). Recently, we identified several
residues in V1, V2 and V3 fHbps which are needed for high
affinity interactions with fH through alanine scanning mutagenesis
[13]. Here we found two further mutations that abolish fH:fHbp
binding by analysing the binding characteristics of a natural
protein.
Figure 5. Immune responses against isogenic N. meningitidis strains. (A) Western blot analysis of whole cell lysates of fHbp expressed by
isogenic MC58Dfhbp strains detected by anti-Ghfp serum. (B) Surface expression of different fHbps in the isogenic MC58Dfhbp strains detected by
flow cytometry. Graph shows the mean 6 SEM of three separate experiments. (C) Representative corresponding flow cytometry overlay of MC58
(grey hatched area), MC58Dfhbp and MC58Dfhbp+fhbp V1.1 detected by anti-Ghfp by flow cytometry. (D) SBA responses against isogenic MC58
strains for anti-Ghfp, fHbp V1.1, and fHbp V3.45 serum using rabbit complement; NK, no killing. (E) SBA responses against isogenic H44/76 strains
with anti-Ghfp serum using rabbit complement.
doi:10.1371/journal.ppat.1003528.g005
Gonococcal Homologue of fHbp
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While fHbp is located on the surface of the meningococcus, we
demonstrate that Ghfp is not on the external surface of the
gonococcus, as suggested previously [17]. Examination of Ghfp
also reveals the absence of a signal sequence for export so the
protein is likely to remain intracellular and not secreted into the
extracellular milieu. We can however not exclude the possibility
that the location of Ghfp changes during infection. The function of
Ghfp remains unknown, although due to its high level of identity
to fHbp, we cannot exclude that Ghfp promotes survival in the
presence of antimicrobial peptide LL-37 [30] or has a role in
siderophore binding [31]. However, these are unlikely functions
for Ghfp given the location of the protein.
fHbp is a key component of protein sub-unit meningococcal
vaccines under late phase clinical development [8,9,32–34].
Unfortunately, antibody responses against fHbp are thought to
be largely variant/family specific. Therefore fHbp-based vaccines
consisting of a single natural fHbp might be expected to have
limited coverage. To overcome this issue, vaccines under
development have included fHbp together with other antigens
namely GNA2132, NadA, GNA1030, GNA2091 and a mem-
brane vesicle [35], or multiple fHbp variants [9]. Here, we show
that anti-sera raised against Ghfp has the potential to recognize
representative V1, V2 and V3 fHbps, in contrast to sera raised
against the widely used V1.1 fHbp and V3.45 fHbp [8]. More
importantly, we showed that Ghfp has the potential to elicit SBA
against wild-type N. meningitidis, and two different strains express-
ing the most common V1, V2 and V3 fHbps. SBA of murine
immune sera was assayed in the presence of rabbit complement.
Although a heterologous non-human source, rabbit complement
has been used to validate the immunogenicity of conjugate
vaccines in pre-clinical and clinical studies [36]. Furthermore, V1
fHbps differ in their recognition by sera raised against Ghfp
(Figure 4A) but this cannot be explained at the level of overall
sequence identity as the proteins we examined are all approxi-
mately 60% identical to Ghfp. The advantage of using isogenic
strains over naturally occurring isolates is that this approach allows
analysis of the effect of diversity in protein sequence on cross-
protective responses, while excluding strain-specific, confounding
factors such as levels of expression and other mechanisms of
immune escape [37]. This breadth of activity was an unexpected
finding which has been seen with synthetic fHbp molecules
containing epitopes from different fHbp variants [38,39] and is not
the result of overexpression of fHbp in our isogenic strains; anti-
sera raised against V1.1 only has SBA against V1.1 and V1.4 in
line with previous results [14], while our work showed that sera
raised against V3.45 was able to elicit SBA against strains
expressing V2.16 and V2.19, again consistent with previous work
demonstrating that raised anti-V3.45 fHbp serum does have SBA
against some V2 fHbp expressing strains [14].
The mechanism underlying the broad protection of Ghfp is
currently unknown. Based on the position of invariant amino acids
in different fHbps, the protein has also been divided into five
variable segments, designated as VA-VE. Using these five
segments, fHbps can be categorized into six modular groups
[40]. A closer inspection of the fHbps expressed in our isogenic
strains reveals that all alleles and Ghfp harbour an identical
variable segment D (VD). However, this common sequence cannot
be the basis of the cross-protection offered by Ghfp as fHbp V3.45
and V1.1 also harbour this region yet do not provide the same
breadth of SBA. Another possibility is that the immunogenic
properties of Ghfp are not solely dependent on its primary amino
acid sequence but instead a result from its conformation. For
instance, it is possible that due to D318 or other residues, the
folding of Ghfp is altered compared with V3.45, altering
accessibility of certain regions of fHbp to B cell receptors and
therefore inducing cross-protective responses. We also compared
Ghfp and fHbp V3.45 with the rationally designed fHbp that
showed broad cross-protection due to introduction of V2 and V3
epitopes into V1.1 fHbp [39]. However all the amino acids
introduced into V1.1 to obtain the cross-protection are present in
both Ghfp and fHbp V3.45 and so cannot explain the cross-
protection we observed with Ghfp.
In summary, Ghfp is a promising vaccine candidate against N.
meningitidis since the protein not only offers a broad range of
protection, but is also a naturally occurring non-fH binding
molecule. There are potential drawbacks for the use of functional
fHbps as a vaccine antigen due to its high affinity binding with fH.
The extensive binding of fH to fHbp could shield immunogenic
epitopes on the antigen resulting in less effective antibody
responses [12]. Moreover, binding of fHbp to fH might reduce
the immunogenicity at the site where antibody responses are
initiated [41] or it could lead to formation of anti fH responses in
the human host [42]. Indeed, non-functional fHbps have
demonstrated non-inferior or enhanced immunogenicity com-
pared with wild-type proteins in transgenic mice [13,43], although
any benefit of these antigens and Ghfp will need to be assessed in
clinical trials.
Materials and Methods
Bacterial strains and growth
The bacterial strains used in this work are shown in Table 1 and
Table 2. N. meningitidis was grown in the presence of 5% CO2 at
37uC on Brain Heart Infusion (BHI, Oxoid, Basingstoke, United
Kingdom) plates with 5% (vol./vol.) horse serum (Oxoid) or in
BHI broth at 37uC. N. gonorrhoeae was grown in the presence of 5%
CO2 at 37uC on GC agar (Oxoid) plates with Vitox (Oxoid) or in
GC broth (15 g Protease peptone (Oxoid), 4 g K2HPO4, 1 g
KH2PO4, 5 g NaCl per litre (Sigma Aldrich) with 10 ml Kellogg’s
supplement (40 g glucose, 0.5 g glutamine, 50 mg Fe(NO3)9H2O,
1 ml 0.2% thiamine pyrophosphate per 100 ml, Sigma Aldrich).
N. gonorrhoeae strains were obtained from across the UK in 2012,
and provided by the Sexually Transmitted Bacterial Reference
Unit, Public Health England (kind gift of Dr. Ison and Dr. Quaye).
Escherichia coli was grown on LB agar plates or LB liquid at 37uC
with appropriate antibiotics.
Generation of mutant strains
Strain MC58Dfhbp [44] and H44/76Dfhbp (constructed as
MC58Dfhbp) were complemented with pGCC4 [45] containing
fhbp V1.1, 1.4, 1.13, 2.16, 2.16, 3.45 and 3.47. PCR to amplify fhbp
was performed using genomic DNA from strains listed in Table 1
and using primers in Table 3. PCR products were ligated into
pGEMT (Promega) then pGCC4. Transformation of N. meningitidis
strain MC58DfHbp was performed as described previously [46].
M1239Dfhbp was constructed as MC58Dfhbp and F62Dghfp was a
kind gift of Dr. M Pizza (Novartis).
Western blot analysis of fHbp
N. meningitidis was grown overnight and re-suspended in
phosphate buffered saline (PBS). The concentration of bacteria
was determined by measuring the O.D. at 260 nm of bacterial
lysates in 1% SDS/0.1 M NaOH [46] and adjusted to 109 CFU
per ml. Samples were mixed with an equal volume of 26 SDS-
PAGE loading buffer and boiled for 10 minutes, then run on SDS-
PAGE gels and transferred to Immobilon PVDF membranes
(Millipore). Membranes were blocked with 3% skimmed milk in
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0.01% Tween in PBS (PBS-T) then incubated with primary
(immune sera at a 1:10000 dilution) and subsequently with
secondary antibodies (goat anti-mouse conjugated HRP IgG,
Dako, 1:20000 dilution) all in PBS-T with 3% skimmed milk. fH
binding to fHbp expressed by N. meningitidis or recombinant
proteins was analysed by far Western blotting. Blots were
incubated with normal human serum (diluted 1:100) for 45 min-
utes, then incubated with anti-fH (Quidel 1:1000 dilution),
followed by rabbit anti-goat-HRP conjugated IgG (Santa Cruz
1:20000 dilution). Binding of secondary antibodies was detected
using the ECL kit (Amersham).
Expression and purification of recombinant Ghfp and
fHbp
Genes were amplified without their signal sequence by PCR
with genomic DNA using primers described in Table 3. PCR
products were ligated into pGEMT then into pET28a (Invitrogen,
after digestion with BamHI and EcoRI) or pET21b (Invitrogen,
using HindIII and XhoI, or NdeI and XhoI). Proteins were expressed
in E. coli and purified using Nickel affinity chromatography
followed by a HiTrapQ HP column (GE Healthcare) [13].
Mutations were introduced into ghfp by overlapping PCR and into
fHbp by QuikChange Site-Directed mutagenesis (Agilent Tech-
nologies) using primers described in Table 3.
Table 1. N. meningitidis and N. gonorrhoeae isolates.
N. meningitis
Strain fHbp Allele ST CC Year Group
MC58 1.1 74 32 1983 B
MC58Dfhbp B
H44/76 1.1 32 32 1976 B
H44/76Dfhbp B
M1239 3.28 437 41/44 1994 B
m1239Dfhbp B
M00.242922 1.4 41 41/44 2000 B
M01 240185 1.10 4 cc11 2001 B
M07 0240624 1.13 6781 N/A 2007 B
M01 240101 1.15 1049 269 2001 B
M07 0240839 1.61 1163 269 2007 B
M07 0240675 1.292 269 269 2007 B
M01.240013 2.19 1159 2001 B
M07 0240625 2.21 1466 174 2007 Y
M07 0240686 2.22 7779 11 2007 C
5/99 2.23 1349 8 1999 B
M07 0240877 3.30 1214 cc269 2007 B
M07 0240606 3.45 213 cc213 2007 B
M07 0240688 3.47 1946 cc461 2007 B
M08 0240023 3.84 6788 cc41/44 2008 B
N. gonorrhoeae
Strain fHbp Allele ST CC Year Group
F62 1900
F62Dghfp
FA1090 1899
doi:10.1371/journal.ppat.1003528.t001
Table 2. E. coli strains used in this study.
E. coli
Strain Plasmid Insert Mutation Source
BL21 pET28b Ghfp This Study
BL21 pET28b GhfpM1 R176Q This Study
BL21 pET28b GhfpM1–2 R176Q, D199G This Study
BL21 pET28b GhfpM1–3 R176Q, D199G, D212S This Study
BL21 pET28b GhfpM1–4 R176Q, D199G, D212S,
R288H
This Study
BL21 pET28b GhfpM1–5 R176Q, D199G, D212S,
R288H, D318G
This Study
BL21 pET28b GhfpM4 R288H This Study
BL21 pET28b Ghfp M5 D318G This Study
BL21 pET28b GhfpM4–5 R288H, D318G This Study
BL21 pET21b fHbp V3.45 This Study
BL21 pET21b fHbpM4 H288R This Study
BL21 pET21b fHbpM5 G318D This Study
BL21 pET21b fHbpM4–5 H288R, G318D This Study
doi:10.1371/journal.ppat.1003528.t002
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Surface Plasmon Resonance (SPR)
SPR was performed using a Biacore 3000 (GE Healthcare).
Ghfp (50 mg/ml) was first digested with 0.5 mg/ml trypsin for
2 hours at room temperature under constant shaking (300 rpm),
then 0.1 mg/ml Pefabloc SC plus (Roche) was added and
incubated for 10 minutes prior to dialysis against PBS. Recom-
binant proteins were immobilized on a CM5 sensor chip
(approximately 600–1000 RU) (GE Healthcare) and increasing
concentrations of fH6–7 (0.5 nM–32 nM) were injected over the
flow channels (40 ml/min). Dissociation was allowed for 300 sec-
onds. BIAevaluation software was used to calculate the KD.
ELISAs
Proteins (3 mg/ml, 50 ml per well) were coated on the surface of
wells (F96 maxisorp, Nunc), and after blocking with 4% BSA in
PBS-T, anti-Ghfp serum was added at different dilutions and
detected with goat anti-mouse HRP antibody (1:5000 diluted)
followed by substrate (Becton Dickinson). To measure fH binding
to Ghfp and fHbp, proteins were coated onto wells (3 mg/ml, 50 ml
per well), then incubated with fH (1 mg/ml, Sigma) and fH binding
was detected using anti-fH poly clonal antibody (Quidel, 1:1000
dilution) followed by an HRP-conjugated rabbit anti-goat IgG
(Dako, 1:5000 dilution).
Table 3. Oligonucleotides used in this study.
Primer Name Sequence (restriction site underlined)
Ghfp F GCGGATCCATGACTAGGAGTAAAC
Ghfp R GCGAATTCCTACTGTTTGTCGGCG
fHbp V3.45 F CGCGGATCCCATATGAGCAGCGGAAGCGGAAGC
fHbp V3.45 R GCCCAAGCTTCTGTTTGCCGGCGATGCC
Ghfp M1F GGT GCC CTA CAG ATT GAA AAA
Ghfp M1R TTT TTC AAT CTG TAG GGC AAC
Ghfp M2F CTTGTCAGCGGCTTGGGCGGA
Ghfp M2R TCCGCCCAAGCCGCTGACAAG
Ghfp M3F CAACTGCCTGGCGGCAAAGCC
Ghfp M3R GGCTTTGCCGCCAGGCAGTTG
Ghfp M4F GAAGAGAAAGGCACTTACCACCTCGCCCTTTTCGGCGAC
Ghfp M4R GTCGCCGAAAAGGGCGAGGTGGTAAGTGCCTTTCTCTTC
Ghfp M5 R GCGAATTCCTACTGTTTGCCGGCG
fHbp V3.45 M4F GAAAAAGGCACTTACCGCCTCGCTCTTTTCGGC
fHbp V3.45 M4R CTTTTTCCGTGAATGGCGGAGCGAGAAAAGCCG
fHbp V3.45 M5F GAAATCGGCATCGCCGACAAACAGAAGCTTGCG
fHbp V3.45 M5R CTTTAGCCGTAGCGGCTGTTTGTCTTCGAACAC
pGCC4V1.1F CGGTTAATTAAGGAGTAATTTTTGTGAATCGAACTGCCTTCTGCT
pGCC4V1.4F CGGTTAATTAAGGAGTAATTTTTGTGAACCGAACTGCC
pGCC4V1.15F CGGTTAATTAAGGAGTAATTTTTGTGAACCGAACTACC
pGCC4V2.16F CGGTTAATTAAGGAGTAATTTTTGTGAACCGAACTGCCTTCTGCT
pGCC4V3.47F CGG TTAATTAAGGAGTAATTTTTGTGAACCGAACTACC
pGCC4V1.1R CGGTTAATTAATTATTGCTTGGCGGC
pGCC4V1.4R CGGTTAATTAATTACTGCTTGGCGGCAAGAC
PGCC4V1.15R CGGTTAATTAATTATTGCTTGGCGGCAAGAC
PGCC4V2.16R CGGTTAATTAACTACTGTTTGCCGGCGATGC
fHbp V1.10 F CGCGGATCCCATATGGTTGCCGCCGACATCG
fHbp V1.10 R CCCGCTCGAGCTGCTTGGCGGCAAGAC
fHbp V1.13 F CCCGCTCGAGCTGCTTGGCGGCAAGAC
fHbp V1.13 R CCCGCTCGAGCTGCTTGGCGGCAAGAC
fHbp V1.15 F CGCGGATCCCATATGGTCGCCGCCGACATCG
fHbp V1.15 R CCCGCTCGAGTTGCTTGGCGGCAAGAC
fHbp V1.61 F CGCGGATCCCATATGGTCGCCGCCGACATTG
fHbp V1.61 R CCCGCTCGAGTTGCTTGGCGGCAAGAC
fHbp V1.229 F CGCGGATCCCATATGGTCGCCGCCGACATCG
fHbp V1.292 R CCCGCTCGAGCTGCTTGGCGGCAAGAC
fHbp V2/V3 F CGCGGATCCCATATGGGCCCTGATTCTGACCGCCTGCAGCAGCGGAGGGTCGCCGCCGACATCGG
fHbp V2 R CCCGCTCGAGCTGTTTGCCGGCGATGCC
fHbp V3 R GCCCAAGCTTCTGTTTGCCGGCGATGCT
doi:10.1371/journal.ppat.1003528.t003
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Generation of anti-Ghfp sera
Six female BALB/C mice (6–8 week old, Charles Rivers,
Margate) were immunised with antigens (20 mg) absorbed to
aluminium hydroxide (final concentration 3 mg/ml), 10 mM
Histidine-HCL, 2 M NaCl (final concentration 9 mg/ml) in
ndistilled H2O and mixed overnight at 4uC. The antigens were
given via the intraperitioneal route on days 0, 21 and 35. Sera
were collected on day 49 by terminal anaesthesia and cardiac
puncture. All procedures were conducted in accordance with
Home Office guidelines.
Serum Bactericidal Assay (SBA)
N. meningitidis was grown on BHI plates supplemented with
1 mM IPTG overnight and suspended in PBS supplemented with
0.1% glucose (PBS-G) to a final concentration of 56104 CFU/ml.
Bacteria were mixed with an equal volume of baby rabbit
complement (Cedarlane) diluted 1:10 in PBS-G. Heat inactivated
serum, pooled from at least six mice was added to the wells.
Control wells contained either no serum or no complement.
Following incubation for 1 hour at 37uC in the presence of 5%
CO2, 10 ml from each well was plated onto BHI plates in duplicate
and the number of surviving bacteria were determined. SBA was
performed with two-fold dilutions of serum starting at 1:32. The
bactericidal activity was expressed as the dilution of serum needed
to kill more than 50% of bacteria in three independent
experiments. Killing was calculated by comparing the number of
surviving bacteria with those recovered from wells containing
complement only.
Surface protein digestion
N. gonorrhoeae strain F62 was grown overnight in GC liquid at
37uC then diluted 1:20 and grown for approximately six hours
until an OD A600 of approximately 0.5. An aliquot (1 ml) of the
bacterial culture was centrifuged at 13,0006 g then re-suspended
in 300 ml of 3 ng/ml Proteinase K (Qiagen) or 3 times dilutions
from this. After incubation for 30 minutes at 37uC, Pefablock SC
inhibitor (Roche, final concentration 1 mM) was added for
15 minutes at room temperature. Samples were then spun and
suspended in 100 ml 16 sample buffer. Digestion was assessed by
Western blot analysis with antibodies against Ghfp (1:10000
diluted), RecA (Abcam, 1:5000 diluted), and a-Lst [18] (1:20000)
followed by goat anti-rabbit (Santa Cruz Technology, 1:20000) or
goat anti-mouse HRP conjugated IgG (Dako, 1:20000). The
relative amounts of full length protein after incubation with
reducing concentrations of proteinase K was measured using
AIDA software.
Flow cytometry
Bacteria (16109) were fixed in 1 ml of 3% formaldehyde for two
hours then washed with PBS. To measure fHbp expression, 56107
bacteria were incubated with 50 ml anti-Ghfp serum (diluted
1:500) in PBS-T for 30 minutes at 4uC with shaking, washed in
PBS-T then incubated with FITC conjugated goat anti-mouse
antibody (DAKO, diluted 1:50) for 30 minutes. After washing,
fHbp expression was measured by flow cytometry using the FACS
calibur, calculating the mean FL1 of 10000 bacteria.
Supporting Information
Figure S1 Alignment of Ghfp and fHbp. Alignment of Ghfp
with fHbp V1,V2 and V3. Sequence alignment is performed with
the protein sequence from after the lipid modification motif in
fHbp and the equivalent position in Ghfp.
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Figure S2 Alignment of Ghfp and fHbp V2 and V3.
Alignment of Ghfp with V2 and V3 fHbps that bind fH with KD in
the nanomolar range. The amino acids that are different in Ghpf
compared to the V2 and V3 proteins are shown in red.
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